O
VIR icon

OrbiMed’s Vir Biotechnology VIR Stock Holding History

OrbiMed’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,380,715
Closed -$14.4M – 132
2025
Q4 		$14.4M Hold
2,380,715
– – 0.29% 70
2025
Q3 		$13.6M Hold
2,380,715
– – 0.32% 65
2025
Q2 		$12M Buy
2,380,715
+132,466
+6% +$710K 0.3% 55
2025
Q1 		$14.6M Sell
2,248,249
-970,368
-30% -$8.63M 0.35% 51
2024
Q4 		$23.6M Sell
3,218,617
-354,383
-10% -$2.8M 0.49% 47
2024
Q3 		$26.8M Buy
3,573,000
+1,252,898
+54% +$10.9M 0.49% 52
2024
Q2 		$20.6M Buy
2,320,102
+1,680,102
+263% +$16.1M 0.41% 60
2024
Q1 		$6.48M Buy
640,000
+539,000
+534% +$5.49M 0.12% 93
2023
Q4 		$1.02M Buy
+101,000
New +$923K 0.02% 105

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

OrbiMed's VIR Position: Q1 2026 in Review

OrbiMed sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 2,380,715 shares — an estimated $14.4M sold.

OrbiMed first reported a position in VIR in Q4 2023 and held it in 9 quarters. The position peaked at $26.8M in Q3 2024. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • OrbiMed reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 2,380,715 Vir Biotechnology shares in Q1 2026, an estimated $14.4M.
  • OrbiMed first reported a position in Vir Biotechnology in Q4 2023 and held it in 9 quarters.
  • OrbiMed's Vir Biotechnology position peaked at $26.8M in Q3 2024.
  • 252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.